The Ebola outbreak in the Democratic Republic of the Congo has now killed more than 4,000 people. Figures released by Congo's health ministry on Thursday, Oct. 1, show 4,018 deaths among 8,300 confirmed cases, making it the fastest-growing Ebola outbreak on record, according to CBS News and the Associated Press.

What makes this outbreak unusual is the virus behind it. It is caused by the Bundibugyo virus, a rarer member of the Ebola family for which no vaccine or treatment has been approved. Existing Ebola tools were built for a different species, and doctors are testing them here without proof that they work.

The World Health Organization rates the global risk as low, and the U.S. Centers for Disease Control and Prevention says the risk to Americans remains low. But the outbreak is a stark example of how a virus thought to live quietly in wildlife can become a regional emergency when it reaches crowded, conflict-hit communities.

A Different Ebola Virus With Fewer Tools

Ebola disease is caused by several related viruses named for where they were found. The best known is Zaire ebolavirus, which drove the West African epidemic of 2014 to 2016. For Zaire virus, there is a licensed vaccine, Ervebo, and approved antibody treatments.

None of those approvals cover Bundibugyo — not the vaccine and not the antibody drugs. Doctors Without Borders notes that the two monoclonal antibody drugs approved after trials in Congo between 2018 and 2020 are specific to Zaire virus and are not effective or approved for this one. Antiviral and antibody candidates exist, but their efficacy has not been proven in clinical trials.

That is why Ervebo is being used here only within research. As of late September, 6,300 health care workers had received the vaccine as part of a clinical trial, and another 1,066 people had also been vaccinated, according to an Africa Centres for Disease Control and Prevention briefing reported by CIDRAP. The vaccine works against Zaire virus, and its effectiveness against Bundibugyo is still being estimated. Congo is also studying remdesivir as a treatment and obeldesivir to prevent infection after exposure.

Without a targeted drug, care relies on basics — fluids, oxygen and close monitoring. Early supportive care can save lives, but many patients reach treatment late.

A Death Rate Near One in Two

The national case fatality rate stands at 48.4%, according to Africa CDC data cited by CIDRAP. In North Kivu province, it is higher, at 59.3%.

Those figures are consistent with what is known about this virus. The World Health Organization reports that the only two earlier Bundibugyo outbreaks, in Uganda in 2007 and Congo in 2012, had fatality rates of 30% and 50%. Bundibugyo disease begins with fever, fatigue, muscle pain, headache, and sore throat, which look like malaria or other common illnesses. That makes early detection hard, and patients are not infectious until symptoms begin.

Conditions on the ground make everything harder. The outbreak is centered in eastern provinces with years of armed conflict and displacement. On Sept. 27, a ruling-party official was beaten to death in Butembo after urging Ebola prevention on the radio, and days later soldiers searching for weapons burned a camp near Bunia that held an Ebola transit center, forcing 19,000 people to flee, CIDRAP reported. Unpaid health workers have protested and gone on strike. At least 50 health workers have died.

Signs of a Slowdown, With Caveats

There are hints of progress. The 278 infections confirmed near the end of September were the lowest weekly count since mid-June, and weekly deaths fell to 192 from a peak of 364 in mid-August. More than 21 days have passed without a new case in 18 health zones.

Officials warn those numbers may be misleading. Wessam Mankoula, an epidemiologist with Africa CDC, said at the briefing that "this curve doesn't mean that the outbreak is totally under control." Insecurity and community resistance in several hotspots have kept teams from doing surveillance, he said, and contact tracing reaches only about 23% of the expected contacts.

The outbreak is also shifting. North Kivu now accounts for nearly 40% of newly confirmed cases, up from 24% at the end of August, according to Doctors Without Borders. A staff member with the group tested positive on Sept. 29 and was flown to the Netherlands for care.

The Wildlife Link and What It Means Beyond Congo

Bundibugyo is a zoonotic virus, meaning it originated in animals. WHO says fruit bats are suspected to be its natural reservoir. People are thought to become infected through close contact with the blood or body fluids of infected wildlife, such as bats or nonhuman primates, after which the virus spreads between people through bodily fluids, unsafe burials, and gaps in hospital infection control. The sources reviewed for this report do not identify the specific animal source of the 2026 outbreak.

For U.S. readers, the CDC says the overall risk to the American public remains low, and the likelihood of Ebola spreading to the United States is very low. No cases linked to this outbreak have been reported in the country. The agency began a public health emergency response on May 17, and WHO, in its June 6 assessment, rated the global risk as low. A case diagnosed in France in June recovered without spreading the virus, and Uganda declared its own outbreak over in July.

Travel rules are strict. According to the CDC's Ebola situation page, updated Oct. 1, travelers who have been in Congo within 21 days of their flight are not allowed to board commercial flights to the United States, and U.S. citizens are told to stay outside Congo for 21 days before entering the country. Travelers from Uganda and South Sudan must enter through designated airports for enhanced screening. The CDC advises against all travel to Ituri and North Kivu provinces.

The next key data will come from WHO situation reports and Africa CDC briefings. Researchers are also waiting on results from the vaccine and treatment trials, which could shape how future Bundibugyo outbreaks are fought. Until then, the response depends on old tools: finding cases, isolating patients, tracing contacts and earning community trust.

What Readers Want to Know

How many people have died in Congo's Ebola outbreak? Congo's health ministry reported 4,018 deaths among 8,300 confirmed cases in figures released on Thursday, Oct. 1.

What is Bundibugyo virus? It is one of several viruses that cause Ebola disease. It was first identified in Uganda in 2007, and this is only the third known outbreak it has caused.

Is there a vaccine for this Ebola outbreak? No vaccine is approved for the Bundibugyo virus. The Ervebo vaccine, approved for a different Ebola species, is being tested in a clinical trial, mainly among health workers.

Why is the death rate so high? About 48% of confirmed cases have died nationally. There is no targeted treatment, early symptoms resemble common illnesses, and conflict delays care and testing.

Where does the virus come from? WHO says fruit bats are suspected to be the natural reservoir. Humans can be infected through contact with infected wildlife, then spread it to others through bodily fluids.

Is the outbreak slowing down? Weekly confirmed cases and deaths have fallen from their peaks, but Africa CDC warns underreporting in insecure areas may hide ongoing transmission.

What does this mean for Americans? The CDC says the risk to the American public is low, and no U.S. cases have been reported. Travelers who were in Congo within the past 21 days cannot board commercial flights to the United States, and the agency advises against all travel to Ituri and North Kivu provinces.